Agomab Therapeutics appoints Dr. Angelika Jahreis to its Board as Independent Director

– BELGIUM, Ghent –  Agomab Therapeutics NV, a company developing differentiated programs with disease-modifying potential in fibrotic diseases, today announced the appointment of Dr. Angelika Jahreis (MD, PhD) to its Board as an Independent Non-Executive Director.

“Angelika’s extensive experience and deep knowledge as a senior drug developer will be of great value to the Board and our company,” said CEO, Tim Knotnerus.

The company also announced the appointment of Dr. Andrea Sáez (PhD) to its executive leadership team as Chief Development Officer, while

Dr. Paolo Michieli (Founder and former CSO) and Dr. Torsten Dreier (former CDO) will remain as senior advisors and members of the Scientific Advisory Board.


Angelika Jahreis is a purpose-driven physician-scientist with over 20 years of drug development expertise at Novartis, Gilead, Genentech, and Amgen, currently serving as SVP, Development Unit Head of Immunology at Novartis. She earned her MD/PhD from the University of Freiburg, Germany, conducted her postdoctoral research at The Scripps Research Institute in La Jolla, and has been honored to serve as a panel member at the FDA JIA Registry and Osteoarthritis Drug Development Workshops.

“Agomab is building a leading company in the field of fibrotic diseases thanks to their innovative programs targeting ALK5 and MET,” said Angelika Jahreis. “Fibrostenosing Crohn’s Disease and Idiopathic Pulmonary Fibrosis are areas of very high unmet medical need and with significant pharma interest.”

About Andrea Sáez

Andrea Sáez was COO/CSO at Origo Biopharma where she led the development of ALK5 inhibitor programs through preclinical and early clinical stages. Following the acquisition of Origo by Agomab in late 2021, she was Head of Portfolio at Agomab and led the development of AGMB-129 into Phase 2 trials. Andrea initiated her academic career with a PhD in Immunology at the Pompeu Fabra University followed by postdoctoral research at Vall d’Hebron Hospital where she published on the therapeutic benefit of TGF-ß inhibitors in cancer. She gained deep understanding of regulatory affairs through supporting various biotechs in CMC, preclinical and clinical regulatory topics in her role as Regulatory Affairs Manager at a leading consultancy firm, after which she became R&D Director at Pangaea Oncology. Before joining Origo Biopharma, Andrea was a Senior Associate at Asabys Partners, supporting several biotech investments, including the investment in Origo.

About Agomab

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in fibrotic diseases.


- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.